RATIONALE: Epicutaneous specific-immunotherapy (EPIT) is a promising treatment for food allergies leading to a higher tolerance threshold. The desensitization process has been shown to be dependent on EPITinduced regulatory T cells and correlated with profound immune deviation. To date, little is known about the contribution of skin dendritic cells to the efficacy of EPIT. METHODS: To address this question, we used a preclinical mouse model of allergy to ovalbumin (OVA) in which sensitized mice were EPIT-treated once a week with OVA-containing patches for 48h over an 8 weeks period. Dynamics and phenotype of skin dendritic cell (skDC) subsets were assessed by flow cytometry and transcriptomics analysis. DC function was further characterized by in vitro T-cell assays and conditional DC-depleted mouse models. RESULTS: Our results show that, while skDC subsets (Langerhans and dermal conventional cDC1 and cCD2) retain their capacity to capture OVA in the skin throughout EPIT treatment, the numbers of OVA+ DCs emigrating towards the draining lymph nodes progressively decreased after 3 to 8 weeks of treatment. In addition, their maturation status was also downregulated, as notably shown by weaker CD86 surface expression. Consequently, EPIT DCs progressively lost their capacity to efficiently prime/reactivate antigen-specific CD4+ Th2 cells, in contrast to Treg stimulation. We are currently investigating the mechanisms by which each skin DC subset subverts the activation of pathogenic type-2 immunity to prevent the development of allergic symptoms. CONCLUSIONS: Taken together, our results open new avenues to better understand the complex mechanisms that leads to the efficacy of EPIT. Children's Hospital Colorado, Aurora, CO. RATIONALE: In the pooled Phase 3, randomized, double-blind, placebocontrolled trials (P3PCT), PEPITES and REALISE, peanut-allergic children aged 4-11 years were treated with daily epicutaneous immunotherapy (EPIT) with a 250-mg peanut patch (VP250) or placebo (PBO). PEPITES assessed EPIT safety and efficacy, while REALISE assessed EPIT safety without requiring food challenges. It is important to establish whether underlying skin disease affects the safety or efficacy profiles of EPIT. METHODS: Post-hoc analysis of the P3PCT explored differences in safety and efficacy among subjects with and without a diagnosis of ongoing atopic dermatitis (AD) at baseline. RESULTS: Treatment-emergent adverse events (TEAEs) were common in P3PCT (92% in VP250; 87% in PBO), consisting primarily of local skin reactions that were clinically managed with mildly potent topical corticosteroids and antihistamines. In the VP250 and PBO arms, respectively, among the AD subjects, 92% and 85% of subjects experienced a TEAE; 92% and 88% in non-AD subjects. In subjects with ongoing AD, there was no increased frequency of a TEAE of eczema distant from the patch site with VP250 (15%) vs PBO (15%); among those without AD, 2% and 1% experienced, respectively. Within PEPITES, differences in Month 12 responder rates between VP250 and PBO were significant in both AD (p<0.001) and non-AD (p<0.01) subgroups. There was no detectable difference in placebo-corrected treatment responders between the subgroups (interaction p-value50.80). CONCLUSIONS: Efficacy assessments were consistently in favor of VP250, irrespective of AD status at study entry. Safety assessments were similar in AD and non-AD subjects.
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RATIONALE:
This study was aimed to analyze the effect of probiotics administrated simultaneously during oral immunotherapy (OIT) in a mouse model of egg allergy. METHODS: C3H/HeJ mice were sensitized by intragastric administration of ovomucoid(OM). As OIT, increasing doses of OM were administered orally to sensitized mice. Lactobacillus casei variety ramnosus (Lcr35) was also administrated. The mice were divided into 4 groups; controls (no OIT), OIT, Lcr35, and OIT plus Lcr35 (OIT+Lcr35). The effect of OIT and Lcr35 treatment was estimated using symptom score, rectal temperature, OM-specific IgE, IgA, IgG1, IgG2a by ELISA and histology stain of small intestine. RESULTS: The severity of anaphylaxis decreased in all treatment groups. Simultaneous administration of Lcr35 during OIT further reduced the severity of anaphylaxis as compared with controls and OIT. The protective effects still remained 2 weeks after off-treatment in all treatment groups. A significant decrease of OM-specific IgA, IgG1 and IgG2a levels in both OIT and OIT+Lcr35 group. However a significant decrease in OM-specific IgE level was observed only in OIT+Lcr35 treated mice, and sustained 2 weeks after off-treatment. Mucin amount in small intestine was reduced by OIT, OIT+Lcr35 and Lcr35 treatment with the lowest level in OIT+Lcr35 group. CONCLUSIONS: We found that Lcr35 treatment during OIT had some synergic effect for protection from anaphylaxis in a mouse model of egg allergy. These findings are need to be confirmed by mouse studies including more detailed immunological profiles and human studies.
